Neuropsychiatric Disorders are clinical diagnoses made by a physician based upon a patient’s presenting symptoms, personal and family history, and various infection-identifying or confirming laboratory tests. When the clinical diagnosis of a Neuropsychiatric Disorder is made or suspected, the clinician can turn to the results of a patient’s Cunningham Panel™ for objective laboratory evidence to support their clinical diagnosis. The Cunningham Panel™ helps identify autoantibodies associated with neuropsychiatric disorders and the capability these autoantibodies have to affect neurologic and neuropsychiatric behavior.
This testing panel was developed based on years of research conducted by Dr. Madeleine Cunningham at the University of Oklahoma with the help of Dr. Susan Swedo at the National Institutes of Mental Health (NIMH). The technology for these tests is exclusively licensed from the University of Oklahoma and was validated and made clinically available in April 2013 through Moleculera Labs. The Cunningham Panel™ is a composite panel of five independent assays or tests.
The collective result of this panel was developed to assist physicians in their diagnosis, and can support an appropriate treatment decision. Due to the complexity of this testing panel, it takes approximately 2-3 weeks to process a specimen and return results to the physician.
Moleculera Labs is based at the University of Oklahoma (OU) Research Park in Oklahoma City, and is currently the only clinical laboratory performing the Cunningham Panel™. Moleculera Labs is accredited by CLIA (Clinical Laboratory Improvement Amendment) and COLA (Commission on Laboratory Accreditation) and licensed to accept physician’s orders from 49 states, with a license application pending in New York State.